Macrolides in cystic fibrosis

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Chronic Respiratory Disease

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1191/1479972305cd066rsPMID 16279156
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical relevance of intracellular and extracellular concentrations of macrolides

  2006cited by this paper
• The Effect of Oral Clarithromycin on Bronchial Airway Inflammation in Moderate-to-Severe Stable COPD

  2004cited by this paper
• The effects of macrolides on inflammatory cells.

  2004cited by this paper
• Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa.

  2004cited by this paper
• Antibiotic Selection Pressure and Resistance in Streptococcus pneumoniae and Streptococcus pyogenes

  2004cited by this paper
• Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma

  2004cited by this paper
• Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis.

  2003cited by this paper
• Interaction of Macrolides and Ketolides with the Phagocytic Cell Line PLB-985

  2003cited by this paper
• Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study.

  2003cited by this paper
• Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

  2003cited by this paper
• Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

  2003cited by this paper
• Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

  2003cited by this paper
• Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial

  2002cited by this paper
• Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

  2002cited by this paper
• Diffuse Panbronchiolitis

  2002cited by this paper
• Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis

  2002cited by this paper
• Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

  2002cited by this paper
• Macrolide antibiotics and pulmonary inflammation.

  2001cited by this paper
• Immunomodulation by Macrolide Antibiotics

  2001cited by this paper
• Comparative safety of the different macrolides.

  2001cited by this paper
• Anti‐inflammatory effects of macrolides in lung disease *

  2001cited by this paper
• Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa

  2001cited by this paper
• Advanced-generation macrolides: tissue-directed antibiotics.

  2001cited by this paper
• Recent advances in cystic fibrosis

  2001cited by this paper
• Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: A pilot study *

  2001cited by this paper
• Azithromycin (AZM) in adults with cystic fibrosis (CF)

  2001cited by this paper
• Clarithromycin Inhibits NF-κB Activation in Human Peripheral Blood Mononuclear Cells and Pulmonary Epithelial Cells

  2001cited by this paper
• Principles of Appropriate Antibiotic Use for Acute Pharyngitis in Adults

  2001cited by this paper
• Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics.

  2001cited by this paper
• Principles of Appropriate Antibiotic Use for Treatment of Acute Bronchitis in Adults

  2001cited by this paper
• Anti-inflammatory effects of macrolide antibiotics.

  2001cited by this paper
• Azithromycin Concentrations in Serum and Bronchial Secretions of Patients with Cystic Fibrosis

  2001cited by this paper
• Buccal Adherence of Pseudomonas aeruginosa in Patients with Cystic Fibrosis under Long-Term Therapy with Azithromycin

  2001cited by this paper
• Azithromycin Inhibits Quorum Sensing in Pseudomonas aeruginosa

  2001cited by this paper
• [Acute exacerbations due to Streptococcus pneumoniae in chronic lower respiratory tract infections during long-term macrolide therapy].

  2001cited by this paper
• Reversal of Anticancer Drug Resistance by Macrolide Antibiotics in Vitro and in Vivo

  2000cited by this paper
• Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells.

  2000cited by this paper
• Azithromycin (AZM) reduced TNF- release from lipopolysachharide (LPS)-stimulated mononuclear cells (PBMC) in cystic fibrosis (CF)

  2000cited by this paper
• Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.

  2000cited by this paper
• Potential role of macrolides in the treatment of asthma.

  2000cited by this paper
• Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells.

  2000cited by this paper
• Effect of Subinhibitory Concentrations of Macrolides on Expression of Flagellin in Pseudomonas aeruginosa and Proteus mirabilis

  2000cited by this paper
• The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes.

  1999cited by this paper
• Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia

  1999cited by this paper
• Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection.

  1999cited by this paper
• Cytokines and Inflammatory Mediators Do Not Indicate Acute Infection in Cystic Fibrosis

  1999cited by this paper
• A pilot study of low-dose erythromycin in bronchiectasis.

  1999cited by this paper
• Erythromycin Inhibits Transcriptional Activation of NF-κB, but not NFAT, through Calcineurin-Independent Signaling in T Cells

  1999cited by this paper
• Fourteen-Member Macrolides Inhibit Interleukin-8 Release by Human Eosinophils from Atopic Donors

  1999cited by this paper
• The anti-inflammatory effects of macrolides

  1999cited by this paper
• Oral Cimetidine Prolongs Clarithromycin Absorption

  1998cited by this paper
• Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin.

  1998cited by this paper
• Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.

  1998cited by this paper
• Long-term azithromycin may improve lung function in children with cystic fibrosis.

  1998cited by this paper
• Therapies aimed at airway inflammation in cystic fibrosis.

  1998cited by this paper
• Azithromycin, the multidrug-resistant protein, and cystic fibrosis.

  1998cited by this paper
• Roxithromycin Inhibits Cytokine Production by and Neutrophil Attachment to Human Bronchial Epithelial Cells In Vitro

  1998cited by this paper
• Erythromycin treatment in diffuse panbronchiolitis.

  1998cited by this paper
• Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

  1998cited by this paper
• Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers.

  1998cited by this paper
• Possible Increased Anticoagulation Effect of Warfarin Induced by Azithromycin

  1998cited by this paper
• Anti-inflammatory activity of macrolides: a new therapeutic potential?

  1998cited by this paper
• Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.

  1998cited by this paper
• Elevated Chlamydia pneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction

  1997cited by this paper
• Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin.

  1997cited by this paper
• International practice patterns by age and severity of lung disease in cystic fibrosis: Data from the epidemiologic registry of cystic fibrosis (ERCF)

  1997cited by this paper
• The use of antibiotics : a clinical review of antibacterial, antifungal, and antiviral drugs

  1997cited by this paper
• Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection.

  1997cited by this paper
• Macrolides reduce the expression of surface Mac-1 molecule on neutrophil.

  1997cited by this paper
• Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells.

  1997cited by this paper
• Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study.

  1997cited by this paper
• Effect of macrolide antibiotics on neutrophil function in human peripheral blood.

  1997cited by this paper
• Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients

  1997cited by this paper
• Macrolides for the treatment of Pseudomonas aeruginosa infections?

  1997cited by this paper
• Identifying Treatments That Halt Progression of Pulmonary Disease in Cystic Fibrosis

  1997cited by this paper
• Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis.

  1997cited by this paper
• Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells

  1997cited by this paper
• Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group.

  1997cited by this paper
• Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes.

  1997cited by this paper
• Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients.

  1997cited by this paper
• Erythromycin, clarithromycin, and azithromycin: are the differences real?

  1996cited by this paper
• Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro.

  1996cited by this paper
• Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy.

  1996cited by this paper
• Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress.

  1996cited by this paper
• Burkholderia cepacia: medical, taxonomic and ecological issues.

  1996cited by this paper
• Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis.

  1996cited by this paper
• Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells

  1996cited by this paper
• Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin

  1996cited by this paper
• Compliance with treatment in adult patients with cystic fibrosis.

  1996cited by this paper
• The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro.

  1996cited by this paper
• [Study on azithromycin in treatment of diffuse panbronchiolitis].

  1995cited by this paper
• Macrolide Antibacterials

  1995cited by this paper
• The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma.

  1995cited by this paper
• Inflammatory cytokines in cystic fibrosis lungs.

  1995cited by this paper
• Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection.

  1995cited by this paper
• Effect of high-dose ibuprofen in patients with cystic fibrosis.

  1995cited by this paper
• Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action.

  1995cited by this paper
• Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells.

  1995cited by this paper
• Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis.

  1995cited by this paper
• Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro

  1994cited by this paper

• Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage

  2022cites this paper
• Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.

  2021cites this paper
• Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.

  2018cites this paper
• STATE OF THE ART Autophagy in Pulmonary Diseases

  2016cites this paper
• The Effect of Intravitreal Azithromycin on the Albino Newborn Rabbit Retina

  2016cites this paper
• Use of macrolides in lung diseases: recent literature controversies.

  2015cites this paper
• Effect of clarithromycin in experimental empyema by multidrug‐resistant Pseudomonas aeruginosa

  2014cites this paper
• Tulathromycin Exerts Proresolving Effects in Bovine Neutrophils by Inhibiting Phospholipases and Altering Leukotriene B4, Prostaglandin E2, and Lipoxin A4 Production

  2014cites this paper
• [Improving cystic fibrosis survival as a result of management in a specialized center with 10-year follow-up].

  2014cites this paper
• The clinical significance of Streptococcus pneumoniae resistance in community-acquired pneumonia Review

  2013cites this paper
• Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment*

  2013cites this paper
• Reduced Nasal Nitric Oxide Production in Cystic Fibrosis Patients with Elevated Systemic Inflammation Markers

  2013cites this paper
• Three cases of infection with pulmonary Mycobacterium Avium complex with resistance to macrolides secondary to prolonged prior use for bronchectasis

  2013cites this paper
• Przydatność praktyczna indeksu przewidywania astmy u dzieci hospitalizowanych z powodu obturacyjnego zapalenia oskrzeli

  2013cites this paper
• Pathogen- and Host-Directed Anti-Inflammatory Activities of Macrolide Antibiotics

  2012cites this paper
• Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients

  2012cites this paper
• Does Erythromycin Have Anti‐Inflammatory Effects Independent of Its Antimicrobial Action?

  2012cites this paper
• Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

  2011cites this paper
• Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

  2011cites this paper
• Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where?

  2011cites this paper
• Anti-inflammatory therapies in bronchiectasis

  2011cites this paper
• TLR5 as an Anti-Inflammatory Target and Modifier Gene in Cystic Fibrosis

  2010cites this paper
• Severe Therapy Resistant Asthma in Children

  2009cites this paper
• Roxithromycin inhibits chemokine-induced chemotaxis of Th1 and Th2 cells but regulatory T cells.

  2009cites this paper
• Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF).

  2009cites this paper
• Roxithromycin antagonizes catagen induction in murine and human hair follicles: implication of topical roxithromycin as hair restoration reagent

  2009cites this paper
• Cystic fibrosis in adults: diagnostic and therapeutic aspects.

  2008cites this paper
• Utilidad de los macrólidos en el manejo de las bronquiectasias: Intervención a favor

  2008cites this paper
• Neutrophils in cystic fibrosis

  2008cites this paper
• Enhanced interleukin-10 signaling with 14-member macrolides in lipopolysaccharide-stimulated macrophages

  2008cites this paper
• Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.

  2008cites this paper
• Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back.

  2008cites this paper
• [New approaches in antibiotic therapies in chronic pulmonary diseases].

  2008cites this paper
• Should Preschool Wheezers Ever Be Treated with Inhaled Corticosteroids?

  2007cites this paper
• The early-life origins of asthma

  2007cites this paper
• [Treatment of airway inflammation in cystic fibrosis].

  2007cites this paper
• Seguiremos teniendo antibióticos mañana

  2007cites this paper
• Traitement de l'inflammation bronchique dans la mucoviscidose

  2007cites this paper
• Daily versus weekly azithromycin in cystic fibrosis patients

  2007cites this paper
• [Will we still have antibiotics tomorrow?].

  2007cites this paper
• Macrolide immunomodulation of chronic respiratory diseases

  2007cites this paper
• Novel Macrolide Resistance Module Carried by the IncP-1β Resistance Plasmid pRSB111, Isolated from a Wastewater Treatment Plant

  2006cites this paper
• Mise au point Immunomodulation médiée par les agents antibactériens Immunomodulatory effects of antibacterial agents

  2006cites this paper
• Immunomodulation médiée par les agents antibactériens

  2006cites this paper
• Azithromycin in Chronic Fatigue Syndrome (CFS), an analysis of clinical data

  2006cites this paper
• Rapidly progressive lung disease in a patient with cystic fibrosis on long-term azithromycin: possible role of mycoplasma infection

  2005cites this paper
• Anti-inflammatory therapy in cystic fibrosis.

  2005cites this paper
• Has the time come to prescribe azithromycin in cystic fibrosis patients?

  2005cites this paper